ATYR

$6.63+5.41%visit website

aTYR PHARMA INC

Market Cap

$650M

Live price × SEC shares (Jul 31, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

1.05

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

13.3

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Revenue	190	0
Research & development	22,130	10,891	7,317	6,748	47,086
Total operating expenses	26,935	14,796	11,436	10,881	64,048
Operating income	(26,745)	(14,796)	(11,436)	(10,881)	(63,858)
Net income	(25,744)	(13,963)	(10,791)	(10,309)	(60,807)
EPS (basic) ($)	(0.26)		(0.11)	(0.11)	(0.63)
EPS (diluted) ($)	(0.26)		(0.11)	(0.11)	(0.63)
Weighted avg. shares (basic)	97,154		98,044	98,070
Weighted avg. shares (diluted)	97,154		98,044	98,070

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 7, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 46 more quarters, back to Mar 2014, with Tormere Pro.

Corporate Events (8-K)

12 filings in 12 months · 3 with priority itemsFull history →

Filed	Items	Filing
Oct 27, 2026 accepted 9:03 AM ET	5.03Bylaws / fiscal year	Document SEC ↗
Oct 16, 2026 accepted 4:02 PM ET	5.07Shareholder vote	Document SEC ↗
Sep 24, 2026 accepted 7:47 AM ET	8.01Other events	Document SEC ↗
Aug 7, 2026 accepted 4:04 PM ET	2.02Earnings release	Document SEC ↗
Jul 31, 2026 accepted 4:44 PM ET	1.02Agreement terminated	Document SEC ↗
Jun 8, 2026 accepted 4:04 PM ET	3.01Delisting notice	Document SEC ↗
Jun 1, 2026 accepted 4:04 PM ET	7.01Reg FD disclosure	Document SEC ↗
May 15, 2026 accepted 8:02 AM ET	2.02Earnings release	Document SEC ↗
May 11, 2026 accepted 4:03 PM ET	2.02Earnings release7.01Reg FD disclosure8.01Other events	Document SEC ↗
Mar 5, 2026 accepted 4:03 PM ET	2.02Earnings release	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

62%

W/W -4.7pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-05-27	2026-05-28	SCHIMMEL PAUL	Director	Purchase	100.0K	$0.50	$50K	779.1K	View
2026-02-04	2026-02-04	Shukla Sanjay	Director & President and CEO	Sale	3,745	$0.98	$4K	153.6K	View
2026-02-04	2026-02-04	Broadfoot Jill Marie	Chief Financial Officer	Sale	1,558	$0.98	$2K	37.3K	View
2026-02-04	2026-02-04	DENYES NANCY	General Counsel	Sale	1,118	$0.98	$1K	33.1K	View
2025-10-09	2025-10-09	SCHIMMEL PAUL	Director	Purchase	318.0K	$0.94	$299K	1.41M	View

1–5 of 6

1 / 2

Recent News

aTyr Pharma(ATYR) Stock Options Chain | Quotes & News

Moomoo · 2026-11-03

471 Forecast — Price Target — Prediction for 2027

TradingView · 2026-11-03

US Session Top Gainers and Losers Led by INLF and AUROW

ChartMill · 2026-11-02

Small-Cap Market Movers: Top Gainers and Losers on Nov. 2, 2026

ChartMill · 2026-11-02

aTyr Pharma Inc (471A.HA) stock historical prices and data

Yahoo Finance UK · 2026-11-02

aTyr Pharma Inc (471A.HA) latest stock news and headlines

Yahoo Finance UK · 2026-10-30

aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT™ Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine

Yahoo · 2026-10-29

Top Market Movers: US Gainers and Losers for October 27, 2026

ChartMill · 2026-10-27

Gap-Up and Gap-Down Stocks in Today's Session

ChartMill · 2026-10-27

aTyr Pharma to implement 1-for-40 reverse stock split

Investing.com · 2026-10-27

Premarket Movers: Gainers and Losers Ahead of Today's US Open

ChartMill · 2026-10-27

aTyr Pharma Announces One-for-40 Reverse Stock Split

Yahoo · 2026-10-27

aTyr Pharma Announces 1-For-40 Reverse Stock Split, Effective Oct. 28

Benzinga · 2026-10-27

aTyr Pharma Announces Research Collaboration with Montefiore Einstein

Yahoo · 2026-10-19

aTyr Pharma Enters Research Collaboration With Albert Einstein College Of Medicine To Develop And Test ATYR2810, Its Monoclonal Antibody That Targets The Neuropilin-2 Receptor

Benzinga · 2026-10-19

Informational purposes only, not investment advice.

ATYR

Financial Statements

Corporate Events (8-K)

Signals

Factor Profile

Recent News

aTYR PHARMA INC (ATYR)

Reporting Insiders

Factor Profile

Corporate Events (8-K)

Date	Insider	Type	Shares	Value
2026-05-27	SCHIMMEL PAUL	P	100,000	$49,630
2026-02-04	Shukla Sanjay	S	3,745	$3,655.12
2026-02-04	Broadfoot Jill Marie	S	1,558	$1,520.61
2026-02-04	DENYES NANCY	S	1,118	$1,091.28
2025-10-09	SCHIMMEL PAUL	P	317,999	$299,364.26